Kathryn A F Pennel, Phimmada Hatthakarnkul, Colin S Wood, Guang-Yu Lian, Sara S F Al-Badran, Jean A Quinn, Assya Legrini, Jitwadee Inthagard, Peter G Alexander, Hester van Wyk, Ahmad Kurniawan, Umar Hashmi, Michael A Gillespie, Megan Mills, Aula Ammar, Jennifer Hay, Ditte Andersen, Colin Nixon, Selma Rebus, David K Chang, Caroline Kelly, Andrea Harkin, Janet Graham, David Church, Ian Tomlinson, Mark Saunders, Tim Iveson, Tamsin R M Lannagan, Rene Jackstadt, Noori Maka, Paul G Horgan, Campbell S D Roxburgh, Owen J Sansom, Donald C McMillan, Colin W Steele, Nigel B Jamieson, James H Park, Antonia K Roseweir, Joanne Edwards
Colorectal cancer (CRC) is a heterogenous malignancy underpinned by dysregulation of cellular signaling pathways. Previous literature has implicated aberrant JAK/STAT3 signal transduction in the development and progression of solid tumors. In this study we investigate the effectiveness of inhibiting JAK/STAT3 in diverse CRC models, establish in which contexts high pathway expression is prognostic and perform in depth analysis underlying phenotypes. In this study we investigated the use of JAK inhibitors for anti-cancer activity in CRC cell lines, mouse model organoids and patient-derived organoids...
March 1, 2024: Journal of Experimental & Clinical Cancer Research: CR